MA44227A - Anticorps pour il-17c - Google Patents
Anticorps pour il-17cInfo
- Publication number
- MA44227A MA44227A MA044227A MA44227A MA44227A MA 44227 A MA44227 A MA 44227A MA 044227 A MA044227 A MA 044227A MA 44227 A MA44227 A MA 44227A MA 44227 A MA44227 A MA 44227A
- Authority
- MA
- Morocco
- Prior art keywords
- antibodies
- fragments
- relates
- antibody
- psoriasis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La présente invention concerne des anticorps ou des fragments d'anticorps se liant à l'il-17c humaine. En particulier, l'invention concerne des anticorps ou des fragments d'anticorps qui présentent des propriétés bénéfiques combinées et sont donc utiles pour le traitement d'êtres humains présentant, par exemple, une dermatite atopique ou un psoriasis.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16156582 | 2016-02-19 | ||
| EP16156651 | 2016-02-22 | ||
| PCT/EP2017/053592 WO2017140831A1 (fr) | 2016-02-19 | 2017-02-17 | Anticorps anti-il-17c |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA44227A true MA44227A (fr) | 2018-12-26 |
| MA44227B1 MA44227B1 (fr) | 2021-06-30 |
Family
ID=58057136
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA44227A MA44227B1 (fr) | 2016-02-19 | 2017-02-17 | Anticorps pour il-17c |
| MA43088A MA43088B1 (fr) | 2016-02-19 | 2017-02-17 | Anticorps anti-il-17c |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA43088A MA43088B1 (fr) | 2016-02-19 | 2017-02-17 | Anticorps anti-il-17c |
Country Status (34)
| Country | Link |
|---|---|
| US (5) | US20190048071A1 (fr) |
| EP (1) | EP3416983B1 (fr) |
| JP (2) | JP6535139B2 (fr) |
| KR (1) | KR102715157B1 (fr) |
| CN (1) | CN108699143B (fr) |
| AU (1) | AU2017219837B2 (fr) |
| BR (1) | BR112018016798A2 (fr) |
| CA (1) | CA3014842A1 (fr) |
| CL (1) | CL2018002340A1 (fr) |
| CO (1) | CO2018008724A2 (fr) |
| CU (1) | CU20180087A7 (fr) |
| CY (1) | CY1124296T1 (fr) |
| DK (1) | DK3416983T3 (fr) |
| EA (1) | EA037813B1 (fr) |
| EC (1) | ECSP18070641A (fr) |
| ES (1) | ES2877376T3 (fr) |
| HR (1) | HRP20211059T1 (fr) |
| HU (1) | HUE054755T2 (fr) |
| IL (1) | IL260733B2 (fr) |
| LT (1) | LT3416983T (fr) |
| MA (2) | MA44227B1 (fr) |
| MD (1) | MD3416983T2 (fr) |
| MX (1) | MX2018009860A (fr) |
| PE (1) | PE20181648A1 (fr) |
| PH (1) | PH12018501739A1 (fr) |
| PL (1) | PL3416983T3 (fr) |
| RS (1) | RS62012B1 (fr) |
| SG (1) | SG11201806161TA (fr) |
| SI (1) | SI3416983T1 (fr) |
| SM (1) | SMT202100361T1 (fr) |
| TN (1) | TN2018000289A1 (fr) |
| TW (1) | TW201734041A (fr) |
| WO (1) | WO2017140831A1 (fr) |
| ZA (1) | ZA201806249B (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2018114657A (ru) * | 2015-10-05 | 2019-11-07 | МорфоСис АГ | Антагонисты IL-17C для лечения и/или предупреждения атопического дерматита |
| CA3014842A1 (fr) * | 2016-02-19 | 2017-08-24 | Morphosys Ag | Anticorps anti-il-17c |
| EP3688031A1 (fr) * | 2017-09-25 | 2020-08-05 | MorphoSys AG | Traitement de la dermatite atopique |
| GB201803563D0 (en) | 2018-03-06 | 2018-04-18 | Galapagos Nv | Antibodies and pharmaceutical compositions thereof for the treatment of autoimmune skin diseases |
| TW202011995A (zh) | 2018-07-03 | 2020-04-01 | 比利時商葛萊伯格有限公司 | 高濃度液體抗體配製物 |
| US20220411465A1 (en) * | 2019-11-22 | 2022-12-29 | Morphosys Ag | Eluate collection during antibody chromatography |
| WO2021099536A1 (fr) * | 2019-11-22 | 2021-05-27 | Morphosys Ag | Procédé pour augmenter le rendement d'anticorps pendant une chromatographie par échange d'ions |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1247080A (fr) | 1983-03-08 | 1988-12-20 | Commonwealth Serum Laboratories Commission | Sequences d'acides amines ayant une activite antigenique |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| JP3614866B2 (ja) | 1997-06-12 | 2005-01-26 | リサーチ コーポレイション テクノロジーズ,インコーポレイティド | 人工抗体ポリペプチド |
| ES2292242T5 (es) * | 1998-05-15 | 2011-05-04 | Genentech, Inc. | Utilizaciones terapéuticas de polipéptidos homólogos de il-17. |
| CA2347973C (fr) | 1999-07-20 | 2010-06-22 | Morphosys Ag | Nouveaux procedes permettant la presentation de (poly)peptides/proteines sur des particules bacteriophages au moyen de liaisons disulfure |
| US7771951B2 (en) | 2001-12-03 | 2010-08-10 | Amgen Fremont Inc. | Antibody categorization based on binding characteristics |
| KR20070084330A (ko) | 2004-10-18 | 2007-08-24 | 지모제넥틱스, 인코포레이티드 | 가용성 zcytor21, 항-zcytor21 항체 및 결합파트너 및 염증에서의 사용방법 |
| WO2007047738A1 (fr) * | 2005-10-18 | 2007-04-26 | Zymogenetics, Inc. | Antagonistes de il-17c et méthodes d'utilisation desdits antagonistes |
| CA2666842A1 (fr) | 2006-10-18 | 2008-04-24 | Zymogenetics, Inc. | Antagonistes de l'il-17c et leurs procedes d'utilisation |
| EP3214442A1 (fr) * | 2010-10-25 | 2017-09-06 | F. Hoffmann-La Roche AG | Traitement de l'inflammation gastro-intestinale, du psoriasis, de l'asthme, et du psoriasis a |
| EP2640742B1 (fr) | 2010-11-19 | 2018-08-15 | MorphoSys AG | Collection de sequences d'anticorps et leur utilisations |
| US20140234330A1 (en) | 2011-07-22 | 2014-08-21 | Amgen Inc. | Il-17 receptor a is required for il-17c biology |
| EP2768859B1 (fr) * | 2011-10-19 | 2018-02-21 | MorphoSys AG | Antagonistes pour l'il17c pour le traitement de troubles inflammatoires |
| WO2013186236A1 (fr) | 2012-06-12 | 2013-12-19 | Orega Biotech | Antagonistes d'isoformes d'il-17 et leurs utilisations |
| EP3233915B1 (fr) * | 2014-12-15 | 2024-08-28 | MorphoSys AG | Anticorps pour il-17c |
| CA3014842A1 (fr) * | 2016-02-19 | 2017-08-24 | Morphosys Ag | Anticorps anti-il-17c |
-
2017
- 2017-02-17 CA CA3014842A patent/CA3014842A1/fr active Pending
- 2017-02-17 RS RS20210775A patent/RS62012B1/sr unknown
- 2017-02-17 WO PCT/EP2017/053592 patent/WO2017140831A1/fr not_active Ceased
- 2017-02-17 BR BR112018016798-3A patent/BR112018016798A2/en not_active Application Discontinuation
- 2017-02-17 PE PE2018001543A patent/PE20181648A1/es unknown
- 2017-02-17 MA MA44227A patent/MA44227B1/fr unknown
- 2017-02-17 EP EP17705873.2A patent/EP3416983B1/fr active Active
- 2017-02-17 HU HUE17705873A patent/HUE054755T2/hu unknown
- 2017-02-17 US US16/076,401 patent/US20190048071A1/en not_active Abandoned
- 2017-02-17 LT LTEP17705873.2T patent/LT3416983T/lt unknown
- 2017-02-17 TN TNP/2018/000289A patent/TN2018000289A1/en unknown
- 2017-02-17 MA MA43088A patent/MA43088B1/fr unknown
- 2017-02-17 JP JP2018543220A patent/JP6535139B2/ja not_active Expired - Fee Related
- 2017-02-17 CN CN201780011965.2A patent/CN108699143B/zh active Active
- 2017-02-17 EA EA201891594A patent/EA037813B1/ru unknown
- 2017-02-17 AU AU2017219837A patent/AU2017219837B2/en active Active
- 2017-02-17 DK DK17705873.2T patent/DK3416983T3/da active
- 2017-02-17 ES ES17705873T patent/ES2877376T3/es active Active
- 2017-02-17 SI SI201730777T patent/SI3416983T1/sl unknown
- 2017-02-17 CU CU2018000087A patent/CU20180087A7/es unknown
- 2017-02-17 KR KR1020187024953A patent/KR102715157B1/ko active Active
- 2017-02-17 HR HRP20211059TT patent/HRP20211059T1/hr unknown
- 2017-02-17 MD MDE20190007T patent/MD3416983T2/ro unknown
- 2017-02-17 TW TW106105384A patent/TW201734041A/zh unknown
- 2017-02-17 SM SM20210361T patent/SMT202100361T1/it unknown
- 2017-02-17 SG SG11201806161TA patent/SG11201806161TA/en unknown
- 2017-02-17 IL IL260733A patent/IL260733B2/en unknown
- 2017-02-17 PL PL17705873T patent/PL3416983T3/pl unknown
- 2017-02-17 MX MX2018009860A patent/MX2018009860A/es unknown
-
2018
- 2018-08-08 US US16/058,143 patent/US10259869B2/en active Active
- 2018-08-16 CL CL2018002340A patent/CL2018002340A1/es unknown
- 2018-08-16 PH PH12018501739A patent/PH12018501739A1/en unknown
- 2018-08-21 CO CONC2018/0008724A patent/CO2018008724A2/es unknown
- 2018-09-17 ZA ZA2018/06249A patent/ZA201806249B/en unknown
- 2018-09-19 EC ECSENADI201870641A patent/ECSP18070641A/es unknown
-
2019
- 2019-02-26 US US16/286,231 patent/US10633439B2/en active Active
- 2019-04-26 JP JP2019086144A patent/JP6916834B2/ja not_active Expired - Fee Related
-
2020
- 2020-03-18 US US16/822,844 patent/US11987621B2/en active Active
-
2021
- 2021-07-06 CY CY20211100604T patent/CY1124296T1/el unknown
-
2024
- 2024-04-15 US US18/635,426 patent/US20250074978A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA44227B1 (fr) | Anticorps pour il-17c | |
| CA3156451A1 (fr) | Anticorps ayant une specificite pour la nectine -4 et leurs utilisations | |
| WO2019224716A8 (fr) | Anticorps spécifiques de gucy2c et leurs utilisations | |
| SA521422581B1 (ar) | أil-7r جسام مضادة للوحدة الثانوية ألفا واستخداماتها | |
| MA40476B1 (fr) | Anticorps et fragments de fixation à l'antigène anti-lag3 | |
| MA46619B1 (fr) | Anticorps anti-il-33 et leurs utilisations | |
| MX2023004869A (es) | Anticuerpos contra sars-cov-2 y usos de los mismos. | |
| MA45029B1 (fr) | Anticorps anti pd-1 et anti-lag3 pour le traitement du cancer | |
| WO2022051591A3 (fr) | Anticorps anti-nectine-4 et leurs utilisations | |
| MY191649A (en) | Antibodies to tigit | |
| EA201792616A1 (ru) | Средства, пути применения и способы лечения синуклеопатии | |
| EA202192101A1 (ru) | Соединения и их применение | |
| ZA202208280B (en) | Antibody molecules to c5ar1 and uses thereof | |
| PH12020551373A1 (en) | Anti-phf-tau antibodies and uses thereof | |
| JOP20220346A1 (ar) | أجسام مضادة عالية الألفة تستهدف فسفرة تاو في سيرين 413 | |
| ZA201807816B (en) | Anti-il-22r antibodies | |
| MX2022001604A (es) | Anticuerpos anti bdca-2. | |
| EA201992688A1 (ru) | Средства, пути применения и способы лечения | |
| ZA202006216B (en) | Antibodies targeting glycoprotein vi | |
| MX2021011040A (es) | Anticuerpos dirigidos contra c5ar. | |
| MA43600A1 (fr) | Anticorps trispecifique anti il-17a,il-17f et une autre molécule anti-inflammatoire | |
| MA47976B1 (fr) | Anticorps dirigés contre trem2 et leur utilisation | |
| MX2024002584A (es) | Tratamientos para la dermatitis atopica. | |
| MA38302B1 (fr) | Anticorps anti-pdgfr-bêta et leurs utilisations | |
| EA202193086A1 (ru) | Ингибиторы аутофагии на основе фениламинопиримидинамида и способы их применения |